The last 10 years of clinical investigation in chronic lymphocytic leukemia (CLL) have established the efficacy of front-line chemoimmunotherapy in inducing remission; improving progression-free survival (PFS); and, with the addition of a
Given the favorable results seen thus far, there is no doubt that the treatment of patients with chronic lymphocytic leukemia is entering an exciting new era with the advent of these novel, relatively nontoxic and nonmyelosuppressive, oral agents.
Incorporation of PD-1 blockade into the treatment algorithms for hematologic malignancies is currently being pursued in multiple active clinical trials. Here we review the data on anti–PD-1 monoclonal antibodies to date and discuss ongoing and future clinical trials.
While the results of the multitude of ongoing PD-1 blockade trials are eagerly awaited, it is clear that research involving the immunotherapy of blood cancers is moving swiftly through this first “checkpoint” at breakneck speed. It is sure to be a fascinating ride.
Dr. Brian Link discusses clinical implications of the large Mayo Clinic/ University of Iowa study (ASCO abstract 8504) showing patient symptoms rather than scheduled surveillance imaging drove detection of relapses in patients with diffuse large B-cell lymphoma (DLBCL).